Stayble Therapeutics (STABL) Q2 2025 earnings summary

Executive summary

• Increased visibility for STA363 through scientific and partnering conferences, with strong interest and engagement from potential partners.

• STA363 is being prepared for a phase 2 clinical trial targeting pain relief in herniated disc patients, following positive phase 1 results showing significant disc volume reduction.

• The company successfully raised SEK 4.55 million in a directed share issue in May, with potential for an additional SEK 2.1–4.2 million if all warrants are exercised.

• Financial resources are secured to support operations and partnership discussions through Q2 2026.

Financial highlights

• Operating expenses for Q2 2025 were SEK 1,882k, down from SEK 3,709k in Q2 2024.

• EBIT for Q2 2025 was SEK -1,860k, an improvement from SEK -3,351k in Q2 2024.

• Net result for Q2 2025 was SEK -1,877k, compared to SEK -3,435k in Q2 2024.

• For the first half of 2025, operating expenses were SEK 3,948k (down from SEK 7,617k), EBIT was SEK -3,904k (improved from SEK -7,250k), and net result was SEK -3,921k (improved from SEK -7,069k) year-over-year.

• Cash and cash equivalents at June 30, 2025, were SEK 5,651k.

Outlook and guidance

• The company aims to finalize phase 2b study plans and continue partnership discussions, with sufficient capital to operate until Q2 2026.

• Ongoing optimization of phase 2 study design with CROs and medical experts to maximize the likelihood of positive results.

• Alternative and complementary partnership opportunities are being evaluated to finance and initiate the phase 2 trial as soon as possible.